BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AM Biotechnologies, LLC Receives Grand Challenges Point-of-Care Diagnostics Grant


12/22/2011 8:23:04 AM

HOUSTON – AM Biotechnologies, LLC (AM Biotech) announced today that it has received a three-year, $1.7 million Point-of-Care Diagnostics grant through Grand Challenges in Global Health, an initiative created by the Bill & Melinda Gates Foundation that seeks to engage creative minds across scientific disciplines — including those who have not traditionally taken part in health research — to work on solutions that could lead to breakthrough advances for those in the developing world. Dr. Ross Durland, Director of Product Development at AM Biotech, will pursue an innovative point-of-care diagnostics project, titled “Ambient-stable X-Aptamer Affinity Agents.”

The Grand Challenges Point-of-Care Diagnostics program provides funding to scientists and researchers worldwide to create technologies and components to assess conditions and pathogens at the point-of-care in the developing world. Dr. Durland’s project is one of 22 Grand Challenges Point-of-Care Diagnostics grants announced Dec. 15.

“New and improved diagnostics to use at the point-of-care can help health workers around the world save countless lives,” said Chris Wilson, Director of Global Health Discovery at the Bill & Melinda Gates Foundation. “Our hope is that these bold ideas lead to affordable, easy-to-use tools that can rapidly diagnose diseases and trigger timelier treatment in resource-poor communities.”

Projects that are receiving funding show promise in creating Point-of-Care Diagnostics that will be easy to use, low cost and otherwise appropriate so that they achieve significant impact and rapid uptake in resource-poor settings.

Dr. Durland’s project will focus on developing X-Aptamer molecules based on chemically modified DNA. They will be used in diagnostic instruments to detect and quantify specific biomarkers of disease in patient samples. X-Aptamers are stable in high temperatures and humidity without special storage conditions, and can be used in a wide range of diagnostic platforms. This makes X-Aptamers very appealing for use in low-resource areas of the world where refrigeration and climate control are not typically available. The chemical modifications used in X-Aptamers are not found in natural DNA but are expected to provide better, more specific binding of the molecules to the targeted biomarkers. Because X-Aptamers are synthesized chemically, they can be easily manufactured in high purity at a very reasonable cost. These highly flexible molecules are compatible with virtually any type of sample and diagnostic detection technology.

About Grand Challenges in Global Health

The Bill & Melinda Gates Foundation recognizes that solving our greatest global health issues is a long-term effort. Through Grand Challenges in Global Health, the Foundation is committed to seeking out and rewarding not only established researchers in science and technology, but also young investigators, entrepreneurs and innovators to help expand the pipeline of ideas to fight diseases that claim millions of lives each year. We anticipate that additional grants will be awarded through the Grand Challenges program in the future.

About AM Biotechnologies, LLC

Established in 2006, AM Biotechnologies, LLC, is a Houston-based, private, for-profit company that uses proprietary processes to develop novel DNA-based affinity capture reagents for all segments of the life science market. For more information about the company and its technologies, visit www.thioaptamer.com.


Read at BioSpace.com


 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->